Browsing Tag
Genmab A/S
3 posts
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
Genmab’s $8bn takeover of Merus: What it means for biotech M&A and the race to control antibody innovation
Find out how Genmab’s $8B acquisition of Merus and its petosemtamab asset is reshaping the oncology biotech race and investor sentiment today.
Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma
Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab…